| Title |
Author |
Type |
Date |
Words |
| An Overlooked Cancer Therapy and Clinical-Trial Opportunity. |
Faloon, William; Strum, Stephen |
|
Aug 13, 2022 |
2303 |
| AstraZeneca granted US approval of Enhertu for HER2-mutant NSCLC. |
|
|
Aug 12, 2022 |
151 |
| Pfizer reports positive top-line results from Phase 3 study of IPD vaccine candidate. |
|
|
Aug 12, 2022 |
234 |
| Pfizer reports positive top-line results from Phase 3 study of IPD vaccine candidate. |
|
|
Aug 12, 2022 |
233 |
| Nabriva Therapeutics completes patient enrollment in Phase 1 trial of XENLETA. |
|
|
Aug 11, 2022 |
156 |
| Greenwich LifeSciences commences Phase III clincial trial of GLSI-100. |
|
|
Aug 11, 2022 |
181 |
| Arbele doses first Australian patient in Phase I ARB202 Study. |
|
|
Aug 11, 2022 |
170 |
| Arbele doses first Australian patient in Phase I ARB202 Study. |
|
|
Aug 11, 2022 |
169 |
| Recbio declares completion of subject enrolment and first dose vaccination in phase III clinical trial of recombinant HPV 9-valent vaccine. |
|
|
Aug 10, 2022 |
208 |
| Recbio declares completion of subject enrolment and first dose vaccination in phase III clinical trial of recombinant HPV 9-valent vaccine. |
|
|
Aug 10, 2022 |
209 |
| LianBio completes enrollment in phase 3 EXPLORER-CN trial of mavacamten. |
|
Clinical report |
Aug 10, 2022 |
282 |
| VYNE announces Phase 2a trial of FMX144 did not meet primary endpoint. |
|
|
Aug 10, 2022 |
233 |
| First Patient Dosed in a Phase 1b Clinical Trial of UPB-101 in Asthma. |
|
|
Aug 10, 2022 |
350 |
| Pfizer, Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15. |
|
|
Aug 10, 2022 |
427 |
| Saol Therapeutics enrols first patient in SL-1002 phase two COMPASS Osteoarthritis Pain Trial. |
|
Clinical report |
Aug 10, 2022 |
191 |
| Saol Therapeutics enrols first patient in SL-1002 phase two COMPASS Osteoarthritis Pain Trial. |
|
Clinical report |
Aug 10, 2022 |
190 |
| Inmagene and HUTCHMED announce start of IMG-004 Phase I trial. |
|
|
Aug 9, 2022 |
163 |
| Sapience Therapeutics conducts sub-study of ST101 Phase 1-2 clinical trial in recurrent and newly diagnosed GBM patients. |
|
|
Aug 9, 2022 |
222 |
| Frontier Biotechnologies announces positive results from FB2001 Phase 1 clinical trial. |
|
Financial report |
Aug 9, 2022 |
179 |
| Inmagene and HUTCHMED announce start of IMG-004 Phase I trial. |
|
|
Aug 9, 2022 |
164 |
| Sapience Therapeutics conducts sub-study of ST101 Phase 1-2 clinical trial in recurrent and newly diagnosed GBM patients. |
|
|
Aug 9, 2022 |
223 |
| Frontier Biotechnologies announces positive results from FB2001 Phase 1 clinical trial. |
|
Financial report |
Aug 9, 2022 |
180 |
| Pfizer and Valneva launch Phase 3 trial of Lyme disease vaccine. |
|
Clinical report |
Aug 9, 2022 |
217 |
| Xilio Therapeutics announces preliminary Phase 1 dose-escalation data for XTX101. |
|
|
Aug 9, 2022 |
261 |
| Veru announces presentation of phase 3 study of Sabizabulin. |
|
Clinical report |
Aug 9, 2022 |
230 |
| Pfizer and Valneva launch Phase 3 trial of Lyme disease vaccine. |
|
Clinical report |
Aug 9, 2022 |
216 |
| Establishment Labs Completes Enrollment in Motiva US IDE Study. |
|
Clinical report |
Aug 8, 2022 |
382 |
| BioNTech reports first-half growth; plans to start trial of Omicron-adapted vaccine. |
|
|
Aug 8, 2022 |
212 |
| BioNTech reports first-half growth; plans to start trial of Omicron-adapted vaccine. |
|
|
Aug 8, 2022 |
213 |
| AstraZeneca, Hutchmed report results from SAVANNAH Phase II trial. |
|
|
Aug 8, 2022 |
153 |
| Zai Lab partner Karuna announces results from Phase 3 EMERGENT-2 trial. |
|
Financial report |
Aug 8, 2022 |
481 |
| Cocrystal Pharma engages CRO to conduct Phase 1a trial with CC-42344. |
|
|
Aug 8, 2022 |
249 |
| Vaccinex announces publication of results of Phase 2 SIGNAL study. |
|
|
Aug 8, 2022 |
544 |
| Amgen says tarlatamab showed 'encouraging antitumor activity' in Phase 1 study. |
|
|
Aug 8, 2022 |
212 |
| Pfizer, Valneva initiate Phase 3 study of Lyme disease vaccine candidate VLA15. |
|
|
Aug 8, 2022 |
184 |
| Ascletis Pharma doses first patient in ASC61 US phase one clinical trial to treat advanced solid tumours. |
|
|
Aug 8, 2022 |
176 |
| Kodiak Sciences completes enrolment of patients in GLOW Phase three tarcocimab tedromer clinical trial. |
|
|
Aug 8, 2022 |
193 |
| Ascletis Pharma doses first patient in ASC61 US phase one clinical trial to treat advanced solid tumours. |
|
|
Aug 8, 2022 |
177 |
| Kodiak Sciences completes enrolment of patients in GLOW Phase three tarcocimab tedromer clinical trial. |
|
|
Aug 8, 2022 |
194 |
| The Value Of Clinical Trials In Drug Development. |
|
|
Aug 7, 2022 |
832 |
| EQRx announces updated data from Phase 3 trial of Sugemalimab. |
|
|
Aug 7, 2022 |
197 |
| Novavax starts Phase 2b/3 Hummingbird global clinical trial to assess Novavax COVID-19 vaccine in younger children. |
|
|
Aug 5, 2022 |
187 |
| Novavax starts Phase 2b/3 Hummingbird global clinical trial to assess Novavax COVID-19 vaccine in younger children. |
|
|
Aug 5, 2022 |
188 |
| Tarsus Pharmaceuticals initiates Phase 2a Eras trial evaluating TP-03. |
|
|
Aug 5, 2022 |
205 |
| ImmunAbs Gains US FDA Approval for a Phase 1 Clinical Trial. |
|
|
Aug 5, 2022 |
324 |
| UKGCC donates GH50,000 towards establishment of clinical trials unit at UGMC. |
|
|
Aug 5, 2022 |
654 |
| BioCryst resumes enrollment in BCX9930 clinical program. |
|
|
Aug 4, 2022 |
183 |
| Astria Therapeutics Initiates Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema. |
|
|
Aug 4, 2022 |
317 |
| Kenya to participate in monkeypox vaccine clinical trials. |
|
|
Aug 4, 2022 |
524 |
| Kenya to participate in monkeypox vaccine clinical trials. |
|
|
Aug 4, 2022 |
519 |
| Jiangsu Recbio Technology announces Philippine approval of comparative study between ReCOV and mRNA vaccines. |
|
|
Aug 3, 2022 |
224 |
| Ipsen: Phase III RESILIENT trial did not meet primary endpoint of OS. |
|
|
Aug 3, 2022 |
158 |
| Landos Biopharma announces top-line results from NX-13 Phase 1b trial. |
|
Financial report |
Aug 3, 2022 |
172 |
| Merrimack: Ipsen says primary endpoint not met in Phase 3 Onivyde trial. |
|
|
Aug 3, 2022 |
189 |
| Cornerstone announces completion of Phase 1b trial of CPI-613. |
|
|
Aug 3, 2022 |
153 |
| Athira Pharma presents data from ACT-AD Phase 2 proof-of-concept study. |
|
|
Aug 3, 2022 |
348 |
| Context Therapeutics signs clinical trial collaboration and supply agreement with The Menarini Group. |
|
|
Aug 3, 2022 |
172 |
| Jiangsu Recbio Technology announces Philippine approval of comparative study between ReCOV and mRNA vaccines. |
|
|
Aug 3, 2022 |
225 |
| Context Therapeutics signs clinical trial collaboration and supply agreement with The Menarini Group. |
|
|
Aug 3, 2022 |
171 |
| EyePoint Pharmaceuticals doses first patient in phase two 'Durasert and Vorolanib in Ophthalmology 2' EYP-1901 clinical trial. |
|
|
Aug 2, 2022 |
294 |
| Tavanta Therapeutics completes patient enrolment for Phase three study of TAVT-45 Granules for Oral Suspension. |
|
|
Aug 2, 2022 |
172 |
| EyePoint Pharmaceuticals doses first patient in phase two 'Durasert and Vorolanib in Ophthalmology 2' EYP-1901 clinical trial. |
|
|
Aug 2, 2022 |
295 |
| Tavanta Therapeutics completes patient enrolment for Phase three study of TAVT-45 Granules for Oral Suspension. |
|
|
Aug 2, 2022 |
173 |
| Context Therapeutics, The Menarini Group announce clinical trial collab. |
|
|
Aug 2, 2022 |
186 |
| Context Therapeutics announces clinical trial collaboration with Menarini Group. |
|
|
Aug 2, 2022 |
186 |
| Innovent Biologics and Laekna Therapeutics dose first patient in phase one/two clinical trial of three-drug combination therapy. |
|
|
Aug 1, 2022 |
237 |
| Lynk Pharmaceuticals doses first participant in LNK01004 phase one clinical study in China. |
|
Clinical report |
Aug 1, 2022 |
170 |
| Innovent Biologics and Laekna Therapeutics dose first patient in phase one/two clinical trial of three-drug combination therapy. |
|
|
Aug 1, 2022 |
236 |
| Lynk Pharmaceuticals doses first participant in LNK01004 phase one clinical study in China. |
|
Clinical report |
Aug 1, 2022 |
169 |
| Concert Pharma reports results for 2nd CTP-543 Phase 3 trial in Alopecia Areata. |
|
Financial report |
Aug 1, 2022 |
350 |
| Otonomy reports results from Phase 2 trial of OTO-313. |
|
|
Aug 1, 2022 |
264 |
| Verrica Pharmaceuticals announces start of Phase 3 trial of VP-102. |
|
|
Aug 1, 2022 |
205 |
| Evofem completes last subject last visit in Phase 3 trial of Phexxi. |
|
|
Aug 1, 2022 |
152 |
| SciSparc signs clinical trial agreement with Yale University. |
|
|
Aug 1, 2022 |
307 |
| Krystal Biotech announces FDA accepted IND application for KB407. |
|
|
Aug 1, 2022 |
163 |
| NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia. |
|
|
Aug 1, 2022 |
619 |
| First Patient Dosed in a Phase 1 Trial Evaluating a Novel Off-the-Shelf Engineered Natural Killer Cellular Therapy for the Treatment of Non-Small Cell Lung Cancer. |
|
|
Aug 1, 2022 |
451 |
| SENSORION INITIATES PROOF OF CONCEPT CLINICAL TRIAL. |
|
|
Jul 30, 2022 |
523 |
| INITIAL IND APPLICATION FOR ASIDNA GRANTED. |
|
|
Jul 30, 2022 |
453 |
| Brit, 39, who flew to US for cancer treatment dies in Texas after it failed to work; Cormac McLaughlin, from Co. Tyrone, passed away after flying to Texas for a clinical trial when he found out he was diagnosed with an aggressive brain tumour. |
By, Sean McPolin |
Obituary |
Jul 30, 2022 |
437 |
| Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial. |
Li, Weiping; Cao, Zhigang; Chang, Pengcheng; Zhang, Bin; Li, Fudong; Chang, Dehui |
|
Jul 30, 2022 |
4058 |
| Sound Pharmaceuticals enrols first patient in SPI-1005 Phase three clinical trial. |
|
|
Jul 29, 2022 |
165 |
| Sound Pharmaceuticals enrols first patient in SPI-1005 Phase three clinical trial. |
|
|
Jul 29, 2022 |
166 |
| Enanta Pharmaceuticals Touts Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19. |
|
|
Jul 29, 2022 |
625 |
| MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan. |
|
|
Jul 28, 2022 |
216 |
| Valbiotis completes recruitment for Phase II/III clinical study with TOTUM-63. |
|
Clinical report |
Jul 28, 2022 |
159 |
| Valbiotis completes recruitment for Phase II/III clinical study with TOTUM-63. |
|
Clinical report |
Jul 28, 2022 |
160 |
| ViiV Healthcare announces data from unblinded phase of HPTN 084 study. |
|
|
Jul 28, 2022 |
492 |
| Drug may slow disease; TEEN ALEX TAKING PART IN TRIALS OF TREATMENT. |
STAFF REPORTER |
|
Jul 27, 2022 |
327 |
| Biomica doses first patient in BMC128 phase one clinical trial. |
|
|
Jul 27, 2022 |
207 |
| Biomica doses first patient in BMC128 phase one clinical trial. |
|
|
Jul 27, 2022 |
206 |
| Cortexyme Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588. |
|
|
Jul 27, 2022 |
380 |
| ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors. |
|
|
Jul 27, 2022 |
382 |
| Ideaya Biosciences, Amgen enter IDE397 clinical trial collaboration. |
|
|
Jul 27, 2022 |
236 |
| Celularity announces treatment of first patient in Phase 1/2a trial of CYNK-101. |
|
|
Jul 27, 2022 |
190 |
| 180 Life Sciences says University of Oxford awarded grant for clinical trial. |
|
|
Jul 27, 2022 |
210 |
| Sling Therapeutics starts enrolment in global Phase 2b LIDS clinical trial of linsitinib. |
|
|
Jul 26, 2022 |
188 |
| Sling Therapeutics starts enrolment in global Phase 2b LIDS clinical trial of linsitinib. |
|
|
Jul 26, 2022 |
187 |
| Seagen and Astellas report positive topline results from phase 1b/2 EV-103 clinical trial of PADCEV combined with Merck's KEYTRUDA to treat advanced urouthelial cancer. |
|
|
Jul 26, 2022 |
355 |
| Seagen and Astellas report positive topline results from phase 1b/2 EV-103 clinical trial of PADCEV combined with Merck's KEYTRUDA to treat advanced urouthelial cancer. |
|
|
Jul 26, 2022 |
356 |
| Immuron reports feedback from FDA regarding IND targeting Campylobacter and ETEC. |
|
|
Jul 26, 2022 |
167 |
| Clearside Biomedical completes dosing in OASIS Phase 1/2a trial of CLS-AX. |
|
|
Jul 26, 2022 |
247 |
| Diffusion Pharmaceuticals to initiate Phase 2 trial in patients with GBM. |
|
|
Jul 26, 2022 |
375 |
| BridgeBio announces interim results from Phase 2 trial of infigratinib. |
|
|
Jul 26, 2022 |
597 |
| Neovasc announces FDA approval of protocol supplement to COSIRA-II trial. |
|
|
Jul 26, 2022 |
394 |
| GenFleet Therapeutics' GFH018 clinical trial applications receive Chinese regulatory approval. |
|
|
Jul 25, 2022 |
232 |
| I-Mab doses first patient in TJ-CD4B Phase clinical trial for patients with solid tumours. |
|
Drug overview |
Jul 25, 2022 |
252 |
| GenFleet Therapeutics' GFH018 clinical trial applications receive Chinese regulatory approval. |
|
|
Jul 25, 2022 |
233 |
| I-Mab doses first patient in TJ-CD4B Phase clinical trial for patients with solid tumours. |
|
Drug overview |
Jul 25, 2022 |
253 |
| AstraZeneca's Tezspire recommended for EU approval for treatment of severe asthma. |
|
|
Jul 25, 2022 |
202 |
| AstraZeneca's Tezspire recommended for EU approval for treatment of severe asthma. |
|
|
Jul 25, 2022 |
201 |
| AstraZeneca's Tezspire recommended for EU approval for treatment of severe asthma. |
|
|
Jul 25, 2022 |
200 |
| AstraZeneca's Tezspire recommended for approval in E.U. by CHMP in severe asthma. |
|
|
Jul 25, 2022 |
176 |
| Sonnet BioTherapeutics announces Phase 1b/2a trial of SON-080 in CIPN. |
|
|
Jul 22, 2022 |
317 |
| First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma. |
|
Clinical report |
Jul 22, 2022 |
160 |
| Bristol Myers Squibb Launches Disability Diversity in Clinical Trials Initiative to Improve Healthcare Outcomes for People with Disabilities. |
|
|
Jul 22, 2022 |
454 |
| LB Announces Publication of Phase 1 Clinical Study of LB-102. |
|
|
Jul 22, 2022 |
319 |
| Yuyu Pharma enrols first patient in YP-P10 phase two clinical study. |
|
|
Jul 21, 2022 |
166 |
| Yuyu Pharma enrols first patient in YP-P10 phase two clinical study. |
|
|
Jul 21, 2022 |
167 |
| Rheos Medicines Receives FDA "Study May Proceed" Letter to Initiate Phase 1 Clinical Study of RHX-317 for Treatment of Autoimmune and Inflammatory Diseases. |
|
|
Jul 21, 2022 |
346 |
| First Patient Dosed in Phase 2 Clinical Trial of Zynlonta in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma. |
|
|
Jul 21, 2022 |
485 |
| First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma. |
|
|
Jul 21, 2022 |
358 |
| Skye Bioscience selects NextPharma as Phase 2 contract drug manufacturer. |
|
|
Jul 21, 2022 |
192 |
| Olema Oncology receives FDA fast track designation for OP-1250. |
|
|
Jul 21, 2022 |
181 |
| Field Trip Health announces first dosings in Phase 1 clinical study of FT-104. |
|
|
Jul 21, 2022 |
275 |
| Celldex announces first patient dosed in Phase 2 study of barzolvolimab. |
|
Clinical report |
Jul 21, 2022 |
213 |
| PharmaCyte Biotech starts 1st phase of two-phase pig study. |
|
|
Jul 21, 2022 |
196 |
| Dice completes enrollment in study of oral IL-17 antagonist, DC-806. |
|
Clinical report |
Jul 21, 2022 |
200 |
| Takeda Touts Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Hyqvia for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). |
|
|
Jul 21, 2022 |
626 |
| PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study. |
|
|
Jul 21, 2022 |
346 |
| Clinical Study on Prevention of Irinotecan-Induced Delayed-Onset Diarrhea by Hot Ironing with Moxa Salt Packet on Tianshu and Shangjuxu. |
Lai, Xianghong; Wang, Anmei |
Clinical report |
Jul 21, 2022 |
5172 |
| VBL Therapeutics Phase 3 ovarian cancer trial misses primary endpoints. |
|
|
Jul 20, 2022 |
232 |
| Skye Bioscience updates Phase 1 timeline. |
|
Chronology |
Jul 20, 2022 |
268 |
| Adial Pharmaceuticals announces results for Onward Phase 3 trial for Ad04. |
|
|
Jul 20, 2022 |
398 |
| Labcorp Expands Automated Clinical Trial Kit Production Line at European Operations Center. |
|
|
Jul 20, 2022 |
300 |
| Arbutus Biopharma plans to continue dosing in triple combination clinical trial. |
|
|
Jul 20, 2022 |
171 |
| ProtoKinetix Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants. |
|
|
Jul 20, 2022 |
165 |
| KGK Science Inks Research Contract with Halucenex for Phase II Clinical Trial. |
|
|
Jul 20, 2022 |
399 |
| Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva Advanced Cervical Scan. |
|
|
Jul 20, 2022 |
324 |
| First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China. |
|
|
Jul 20, 2022 |
659 |
| Patient Dosing Starts in CARDINAL-HF, a Phase 2 Clinical Trial of Cardurion Pharmaceuticals' PDE9 inhibitor in Heart Failure. |
|
|
Jul 19, 2022 |
558 |
| Viking Therapeutics: FDA lifts clinical hold on Phase 1b trial of VK0214. |
|
|
Jul 19, 2022 |
192 |
| Artelo Biosciences completes enrollment of first three cohorts in CAReS study. |
|
Clinical report |
Jul 19, 2022 |
226 |
| Capricor announces first patient dosed in Phase 3 study of CAP-1002. |
|
Clinical report |
Jul 19, 2022 |
191 |
| Sinovac Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile. |
|
|
Jul 19, 2022 |
363 |
| Merck to stop Phase 3 LYNK-003 trial investigating LYNPARZA. |
|
|
Jul 18, 2022 |
189 |
| Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura Presented at American Society of Retina Specialists Meeting. |
|
|
Jul 18, 2022 |
492 |
| Bangavax gets DGDA nod for clinical trial. |
|
|
Jul 18, 2022 |
437 |
| EyePoint Pharmaceuticals reveals 12-month data from Phase 1 'Durasert and Vorolanib in Ophthalmology' (DAVIO) clinical trial assessing EYP-1901. |
|
|
Jul 18, 2022 |
384 |
| Escend Pharmaceuticals' ES-3000 investigational new drug application receives US FDA approval. |
|
|
Jul 18, 2022 |
164 |
| EyePoint Pharmaceuticals reveals 12-month data from Phase 1 'Durasert and Vorolanib in Ophthalmology' (DAVIO) clinical trial assessing EYP-1901. |
|
|
Jul 18, 2022 |
383 |
| Escend Pharmaceuticals' ES-3000 investigational new drug application receives US FDA approval. |
|
|
Jul 18, 2022 |
163 |
| Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial. |
|
|
Jul 18, 2022 |
179 |
| The Lancet Oncology Publishes Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy. |
|
|
Jul 18, 2022 |
910 |
| Grail and National Health Service England Complete Enrollment of 140,000 Participants in Largest Study of Multi-Cancer Early Detection Test. |
|
|
Jul 18, 2022 |
653 |
| Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial. |
Yang, Bo; Guo, Xiaofeng; Le, Cheng; Su, Wenzhong; Li, Xiaoming; Zhang, Yanfeng; Yang, Guangyi; Liang |
Report |
Jul 18, 2022 |
4359 |
| Bridging Experience and Expertise: A Case Study of COVID-19 Vaccine Trial Participation and Social Media Vaccine Communication. |
Campeau, Kari |
Case study |
Jul 17, 2022 |
9664 |
| DGDA approves Bangavax for clinical trial in 1st phase. |
|
|
Jul 17, 2022 |
315 |
| Rishi Sunak targets scrapping EU laws in fresh pitch to Brexiteers; Former chancellor indicated he would overhaul data protection rules and speed up clinical trials. |
By, Gavin Cordon, PA Whitehall Editor & Shane Jarvis |
|
Jul 17, 2022 |
592 |
| Omega Therapeutics' OTX-2002 Investigational New Drug application receives US FDA approval to start phase one/two, first-in-human, clinical study. |
|
|
Jul 15, 2022 |
200 |
| Omega Therapeutics' OTX-2002 Investigational New Drug application receives US FDA approval to start phase one/two, first-in-human, clinical study. |
|
|
Jul 15, 2022 |
199 |
| HUTCHMED doses first patient in Phase I trial of HMPL-A83 in China. |
|
|
Jul 15, 2022 |
167 |
| HUTCHMED doses first patient in Phase I trial of HMPL-A83 in China. |
|
|
Jul 15, 2022 |
166 |
| First Patient Dosed in Phase 1 Study for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor I[+ or -] for the Treatment of Advanced Solid Tumors. |
|
|
Jul 15, 2022 |
447 |
| EyePoint reports 'positive' 12-month data from Phase 1 trial of EYP-1901. |
|
|
Jul 15, 2022 |
312 |
| Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia. |
|
|
Jul 15, 2022 |
363 |
| Efficacy of High-Dose Vitamin C Infusion on Outcomes in Sepsis Requiring Mechanical Ventilation: A Double-Blind Randomized Controlled Trial. |
El Driny, Wessam A.; Esmat, Ibrahim M.; Shaheen, Sara M.; Sabri, Nagwa A. |
|
Jul 15, 2022 |
7394 |
| Phase 3 Study Results in People with COVID-19 Shows SaNOtize Nitric Oxide Nasal Spray Reduced Viral Load by 99% within Two Days. |
|
|
Jul 14, 2022 |
730 |
| Summit Therapeutics plans to explore additional clinical trial for ridinilazole. |
|
|
Jul 14, 2022 |
174 |
| Revelation Biosciences completes data base lock for its Phase 1b CLEAR study. |
|
|
Jul 14, 2022 |
181 |
| ABVC BioPharma provides ADHD Phase II Part 2 clinical update. |
|
Clinical report |
Jul 13, 2022 |
156 |
| Novan announces publication of 'positive' Phase 3 results in JAMA Dermatology. |
|
Clinical report |
Jul 13, 2022 |
249 |
| Tetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome. |
|
Clinical report |
Jul 13, 2022 |
473 |
| Aculys Pharma and Susmed Ink Contract to Conduct the World's First Clinical Trial Utilizing Blockchain Technology. |
|
|
Jul 13, 2022 |
692 |
| No adverse events at COVID vaccine trials so far: Bio Farma. |
|
|
Jul 13, 2022 |
320 |
| Phase 3 trial of Merah Putih vaccine on in Padang Pariaman. |
|
|
Jul 13, 2022 |
361 |
| Rhythm announces interim results from Phase 2 trial of setmelanotide. |
|
|
Jul 12, 2022 |
268 |
| Aldeyra: Primary endpoints in DED chamber crossover clinical trial achieved. |
|
|
Jul 12, 2022 |
321 |
| Dyne announces clearance of clinical trial application for DYNE-101. |
|
|
Jul 12, 2022 |
199 |
| Cybin begins trial enrollment for CYB003 study for MDD treatment. |
|
|
Jul 12, 2022 |
210 |
| Y-mAbs Therapeutics announces clearance of IND for GD2-SADA. |
|
|
Jul 12, 2022 |
216 |
| Apyx Medical Posts Results of the US IDE Clinical Study Evaluating the Use of Renuvion to Improve the Appearance of Lax Skin in the Neck and Submental Region. |
|
Clinical report |
Jul 12, 2022 |
263 |
| Surgical Parameters Related to Excessive Intrarenal Pressure during Minimally Invasive Percutaneous Nephrolithotomy in the Supine Position: A Prospective Observational Clinical Study. |
Jung, Gyoohwan; Kho, Yongseok; Park, Jae Suk; Yuk, Hyeong Dong; Ryang, Seung Hoon; Cho, Sung Yong |
Report |
Jul 12, 2022 |
4871 |
| First Patient Dosed in China with Zylonta, Rituximab Combination in Global Phase 3 Clinical Trial. |
|
|
Jul 11, 2022 |
552 |
| Evogene announces enrollment of first patient in Phase I study of BMC128. |
|
|
Jul 11, 2022 |
199 |
| Iterum announces SPA agreement with FDA on Phase 3 trial of oral sulopenem. |
|
|
Jul 11, 2022 |
216 |
| Aethlon announces US FDA approval of Hemopurifier study protocol amendment. |
|
|
Jul 11, 2022 |
226 |
| Cybin Closes CDN 1m Acquisition of DMT Clinical Study. |
|
Clinical report |
Jul 11, 2022 |
207 |
| Cybin Closes CDN 1m Acquisition of DMT Clinical Study. |
|
Clinical report |
Jul 11, 2022 |
183 |
| Freeline presents data from first cohort of Phase 1/2 dose-confirmation B-LIEVE. |
|
|
Jul 10, 2022 |
279 |
| Pliant announces safety, efficacy data from Phase 2a INTEGRIS-IPF trial. |
|
Clinical report |
Jul 10, 2022 |
235 |
| Improvements of Physical Activity Performance and Motivation in Adult Men through Augmented Reality Approach: A Randomized Controlled Trial. |
Nekar, Daekook M.; Kang, Hye Yun; Yu, Jae Ho |
Clinical report |
Jul 9, 2022 |
8279 |
| Efficacy and Safety of Tripterygium Wilfordii Glycoside Tablets Combined with Acitretin Capsules in the Treatment of Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial. |
Fu, Qinghui; Zhu, Yunjie; Fang, Yiqi; Dai, Changbo |
|
Jul 9, 2022 |
4324 |
| Sublingual Sufentanil vs. Intravenous Fentanyl for the Treatment of Acute Postoperative Pain in the Ambulatory Surgery Center: A Randomized Clinical Trial. |
Berg, Aaron; Habeck, Jason; Strigenz, Michael; Pearson, Jonah; Kaizer, Alexander; Hutchins, Jacob |
Clinical report |
Jul 8, 2022 |
4094 |
| Prevention of Postoperative Events following Reversal with Sugammadex or Neostigmine (the P-PERSoN Trial): Pilot Data Following Early Termination of a Prospective, Blinded, Randomised Trial. |
Olesnicky, Benjamin; Doane, Matthew; Farrell, Clare; Knoblanche, Greg; Delaney, Anthony |
|
Jul 8, 2022 |
4428 |
| Smartphone Application for Celiac Patients: Assessing Its Effect on Gastrointestinal Symptoms in a Randomized Controlled Clinical Trial. |
Nikniaz, Zeinab; Namvar, Zahra Akbari; Shirmohammadi, Masood; Maserat, Elham |
Clinical report |
Jul 8, 2022 |
4943 |
| InnoCare Receives China Approval of Clinical Trial of Novel Targeted Protein Degrader ICP-490. |
|
|
Jul 8, 2022 |
309 |
| Dosing Begins in Filament Health Psilocin Clinical Trial. |
|
|
Jul 8, 2022 |
266 |
| Burke Neurological Institute Receives a USD 45m NIH Grant to Study a Vitamin B1 Precursor for Treatment of Alzheimer's Disease in Multi-center Clinical Trial. |
|
|
Jul 8, 2022 |
721 |
| Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA. |
|
|
Jul 8, 2022 |
789 |
| MediWound's EscharEx shows positive Phase 2 results in leg ulcers. |
|
Clinical report |
Jul 7, 2022 |
152 |
| Amryt Pharma presents new Phase 3 trial analyses in DEB. |
|
|
Jul 7, 2022 |
152 |
| Biohaven enrolls first patient in Phase 3 trial of taldefgrobep alfa. |
|
|
Jul 7, 2022 |
182 |
| Annovis Bio announces positive FDA notice for buntanetap Phase 3 trial. |
|
|
Jul 7, 2022 |
156 |
| Akari Therapeutics reports first completed treatment in Phase 3 nomacopan trial. |
|
|
Jul 7, 2022 |
199 |
| Miracle treatment changed one man's life in lockdown trial -after IBS had 'brought life to a standstill'; Anthony Anderson has spoken of how a new IBS treatment changed his life. |
By, Sam Volpe |
|
Jul 7, 2022 |
781 |
| PS50K COULD GIVE TERMINALLY ILL SARAH HER LIFE McCrimmon BACK; FUNDRAISER LAUNCHED FOR NHS WORKER Nurse, 23, with a rare kidney cancer pins hopes on clinical trial in America. |
CALAM PENGILLY |
|
Jul 7, 2022 |
560 |
| Alterity Therapeutics doses first patient in phase two clinical trial of ATH434 in Multiple System Atrophy. |
|
|
Jul 7, 2022 |
193 |
| Alterity Therapeutics doses first patient in phase two clinical trial of ATH434 in Multiple System Atrophy. |
|
|
Jul 7, 2022 |
194 |
| Common brain supplement could spur on Alzheimer's, study warns; Recent clinical research into dementia has unexpectedly found that one common chemical in brain-boosting supplements can actually lead to the onset of the degenerative brain disease, rather than counter it. |
By, William Morgan |
Clinical report |
Jul 6, 2022 |
403 |
| Inmagene and HUTCHMED report dosing of first participant in global Phase I trial of investigational OX40 antagonistic monoclonal antibody IMG-007. |
|
|
Jul 6, 2022 |
181 |
| Inmagene and HUTCHMED report dosing of first participant in global Phase I trial of investigational OX40 antagonistic monoclonal antibody IMG-007. |
|
|
Jul 6, 2022 |
180 |
| Innocoll Highlights Publication of Positive Results from Pivotal Clinical Trial of Posimir in Arthroscopic Subacromial Decompression. |
|
|
Jul 6, 2022 |
493 |
| Bruker Launches NMR-based Molecular Phenomics Clinical Research Tool for 'Long COVID' Multi-Organ Risk Assessment. |
|
|
Jul 6, 2022 |
395 |
| Artificial Intelligence-Based Data-Driven Strategy to Accelerate Research, Development, and Clinical Trials of COVID Vaccine. |
Sharma, Ashwani; Virmani, Tarun; Pathak, Vipluv; Sharma, Anjali; Pathak, Kamla; Kumar, Girish; Patha |
Report |
Jul 6, 2022 |
12684 |
| Arctic Vision enrols first patient in ARVN003 phase III clinical study. |
|
Clinical report |
Jul 5, 2022 |
180 |
| JW Therapeutics commences phase one clinical study of JWATM204 in advanced hepatocellular carcinoma patients. |
|
Clinical report |
Jul 5, 2022 |
181 |
| Abbisko Therapeutics doses first patient in ABSK061 Phase one clinical trial. |
|
|
Jul 5, 2022 |
169 |
| Arctic Vision enrols first patient in ARVN003 phase III clinical study. |
|
Clinical report |
Jul 5, 2022 |
179 |
| JW Therapeutics commences phase one clinical study of JWATM204 in advanced hepatocellular carcinoma patients. |
|
Clinical report |
Jul 5, 2022 |
180 |
| Abbisko Therapeutics doses first patient in ABSK061 Phase one clinical trial. |
|
|
Jul 5, 2022 |
168 |
| Orexo initiates human clinical study of nasal adrenaline rescue medication OX640. |
|
Report |
Jul 5, 2022 |
154 |
| Orexo initiates human clinical study of nasal adrenaline rescue medication OX640. |
|
Report |
Jul 5, 2022 |
152 |
| Anebulo Pharmaceuticals reports ANEB-001's positive topline data in Phase 2 clinical trial for acute cannabinoid intoxication. |
|
|
Jul 5, 2022 |
320 |
| Orexo initiates human clinical study of nasal adrenaline rescue medication OX640. |
|
Report |
Jul 5, 2022 |
153 |
| Anebulo Pharmaceuticals reports ANEB-001's positive topline data in Phase 2 clinical trial for acute cannabinoid intoxication. |
|
|
Jul 5, 2022 |
321 |
| Anebulo says Phase 2 ANEB-001 clinical trial met primary endpoint. |
|
|
Jul 5, 2022 |
494 |
| Nevro announces 12-month results from SENZA-PDN randomized controlled trial. |
|
Financial report |
Jul 5, 2022 |
269 |
| Fulcrum announces dosing of first patient in Phase 3 trial of losmapimod. |
|
|
Jul 5, 2022 |
267 |
| Ayala announces interim results from Phase 2/3 clinical trial evaluating AL102. |
|
|
Jul 5, 2022 |
252 |
| US FDA Lifts Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes. |
|
|
Jul 5, 2022 |
397 |
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE. |
|
|
Jul 5, 2022 |
339 |
| Anebulo Pharmaceuticals Touts Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication. |
|
|
Jul 5, 2022 |
549 |
| Pre-clinical trial of Merah Putih Vaccine to commence July-end 2022. |
|
|
Jul 5, 2022 |
316 |
| Pre-clinical trial of Merah Putih Vaccine to commence July-end 2022. |
|
|
Jul 5, 2022 |
313 |
| Innovent Biologics doses first ulcerative colitis patient in phase two clinical study of IBI112 in China. |
|
Clinical report |
Jul 4, 2022 |
187 |
| Abbisko Therapeutics completes dosing of first patient in Phase 1 clinical trial in advanced solid tumours for ABSK061. |
|
|
Jul 4, 2022 |
160 |
| Innovent Biologics doses first ulcerative colitis patient in phase two clinical study of IBI112 in China. |
|
Clinical report |
Jul 4, 2022 |
186 |
| Abbisko Therapeutics completes dosing of first patient in Phase 1 clinical trial in advanced solid tumours for ABSK061. |
|
|
Jul 4, 2022 |
159 |
| Roche eyes clinical trials in PH. |
|
|
Jul 4, 2022 |
679 |
| SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China. |
|
|
Jul 4, 2022 |
663 |
| Receptor Life Sciences Announces First Patient Dosed with RLS103 in Phase 1b/2a Clinical Study in Acute Anxiety within Social Anxiety Disorder. |
|
|
Jul 1, 2022 |
294 |
| MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial. |
|
|
Jul 1, 2022 |
177 |
| Axalbion Touts Positive Findings from Phase 2 Clinical Study in Chronic Cough with Novel TRPM8 Agonist. |
|
Clinical report |
Jul 1, 2022 |
616 |
| ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of Zylonta in Combination with Other Anti-cancer Agents. |
|
|
Jul 1, 2022 |
540 |
| Phase I of the DiaVACCS screening trial: Study design, methods, population demographics and baseline results. |
Dreyer, G.; Snyman, L.C.; van der Merwe, F.H.; Richter, K.L.; Dreyer, G.J.; Visser, C.; Botha, M.H. |
Report |
Jul 1, 2022 |
7588 |
| A clinical study on latest trends of psoriasis in patients attending dermatology OPD in a tertiary care center. |
Darsan S, Suruthi Purushothaman, Budeda Hasini, S.S Ravi and V.V.V. Satyanarayana |
Clinical report |
Jun 30, 2022 |
1184 |
| CanariaBio reaches 50% target enrolment for Phase III clinical study of oregovomab to treat front-line advanced ovarian cancer. |
|
Clinical report |
Jun 30, 2022 |
276 |
| CanariaBio reaches 50% target enrolment for Phase III clinical study of oregovomab to treat front-line advanced ovarian cancer. |
|
Clinical report |
Jun 30, 2022 |
275 |
| Sanofi reports patient enrollment of phase 3 tolebrutinib trials paused in U.S. |
|
|
Jun 30, 2022 |
268 |
| Cara Therapeutics announces results from Phase 2 trial of difelikefalin. |
|
|
Jun 30, 2022 |
281 |
| BioRestorative announces first patient enrolled in Phase 2 trial of BRTX-100. |
|
Clinical report |
Jun 30, 2022 |
188 |
| Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan for the Treatment of Non-Muscle Invasive Bladder Cancer. |
|
|
Jun 30, 2022 |
215 |
| PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 in IPF and Advances LYT-200. |
|
Clinical report |
Jun 30, 2022 |
556 |
| Celldex presents positive Phase 1b interim data from barzolvolimab. |
|
|
Jun 30, 2022 |
156 |
| Improvement of fertility outcomes using dexamethasone / antibiotic adjuvant therapy following hysterosalpingography in infertile females: A randomised trial. |
El-Kharoubi Amin-Florin and Szasz Florin |
|
Jun 30, 2022 |
2991 |
| Protocol of Pakistan randomized and observational trial to evaluate coronavirus treatment among newly diagnosed patients with COVID-19: Azithromycin, Oseltamivir, and Hydroxychloquine. |
Shehnoor Azhar, Javed Akram, Muhammad Shahzad, Waqas Latif and Khalid Saeed Khan |
|
Jun 30, 2022 |
4906 |
| The red flag bowel cancer symptoms that Deborah James wanted to highlight as part of lasting legacy; Deborah's Bowelbabe fund has now raised more than £6.8m for clinical trials and personalised medicine for cancer patients. |
By, Cathy Owen & Mark Smith |
|
Jun 29, 2022 |
1352 |
| Soligenix's SGX302 IND clinical trial application receives US FDA approval. |
|
|
Jun 29, 2022 |
200 |
| Soligenix's SGX302 IND clinical trial application receives US FDA approval. |
|
|
Jun 29, 2022 |
199 |
| Aileron Therapeutics reports Phase 1b data of lung cancer candidate ALRN-6924. |
|
|
Jun 29, 2022 |
302 |
| Agenus announces expanded data from Phase 1b study of botensilimab, balstilimab. |
|
|
Jun 29, 2022 |
219 |
| AN2 Therapeutics initiates Phase 2/3 trial evaluating epetraborole. |
|
|
Jun 29, 2022 |
186 |
| Galera Therapeutics announces results from Phase 1 stage of GRECO-1 trial. |
|
Financial report |
Jun 29, 2022 |
317 |
| Trevi Therapeutics' Haduvio meets efficacy endpoint in Phase 2b/3 trial. |
|
|
Jun 29, 2022 |
217 |
| Global Blood Therapeutics initiates Phase 2/3 clinical trial of GBT601. |
|
|
Jun 29, 2022 |
203 |
| Codiak initiates patient dosing in Phase 1 trial of exoASO-STAT6. |
|
|
Jun 29, 2022 |
184 |
| Advaxis announces an update on Phase 1 trial of ADXS-504. |
|
|
Jun 29, 2022 |
250 |
| US FDA Approves Prestige Biopharma's IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510. |
|
|
Jun 29, 2022 |
415 |
| Xingnao Kaiqiao Acupuncture Method Combined with Temporal Three-Needle in the Treatment of Acute Ischemic Stroke: A Randomized Controlled Trial. |
Song, Zhongtao; Huang, Qingyuan; Guo, Yuxia; Song, Xiaodong; Zhang, Xuan; Xiao, Huajun |
|
Jun 29, 2022 |
5374 |
| Phase 3 of Merah Putih clinical trial begins. |
|
|
Jun 28, 2022 |
405 |
| Ceruvia Lifesciences' synthetic psilocybin Phase two clinical trial receives US FDA approval. |
|
|
Jun 28, 2022 |
200 |
| Ceruvia Lifesciences' synthetic psilocybin Phase two clinical trial receives US FDA approval. |
|
|
Jun 28, 2022 |
199 |
| Decibel reports data from interim analysis of Phase 1b trial of DB-020. |
|
|
Jun 28, 2022 |
315 |
| Schrodinger gets FDA clear for IND application or MALT1 inhibitor, SGR-1505. |
|
|
Jun 28, 2022 |
259 |
| Revolution Medicines doses first patient in Phase 1/1b trial of RMC-6236. |
|
|
Jun 28, 2022 |
198 |
| MeiraGTx announces data from the MGT009 Phase 1/2 clinical study. |
|
Clinical report |
Jun 28, 2022 |
263 |
| Icosavax plans to file IND submission and initiate a Phase 1 trial for IVX-A1. |
|
|
Jun 28, 2022 |
209 |
| Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder. |
|
|
Jun 28, 2022 |
377 |
| Daewoong Pharmaceutical's IND for DWN12088 receives FDA approval for phase two clinical trial. |
|
|
Jun 27, 2022 |
192 |
| Daewoong Pharmaceutical's IND for DWN12088 receives FDA approval for phase two clinical trial. |
|
|
Jun 27, 2022 |
193 |
| Astellas Pharma says FDA places clinical hold on FORTIS Phase 1/2 trial. |
|
|
Jun 27, 2022 |
243 |
| Takeda, Arrowhead announce results from Phase 2 study of fazirsiran. |
|
Clinical report |
Jun 27, 2022 |
279 |
| AstraZeneca's Lynparza recommended for E.U. approval by CHMP in breast cancer. |
|
|
Jun 27, 2022 |
178 |
| Tonix Pharmaceuticals announces trial design of new TNX-1300 Phase 2 study. |
|
Clinical report |
Jun 27, 2022 |
368 |
| Cybin receives FDA IND clearance for Phase 1/2a trial evaluating CYB003. |
|
|
Jun 27, 2022 |
166 |
| Otsuka, Lundbeck announce results from Phase 3 trial of brexpiprazole. |
|
|
Jun 27, 2022 |
153 |
| Sellas Life Sciences provides clinical update for GFH009 ongoing Phase 1 trial. |
|
|
Jun 27, 2022 |
257 |
| Acer Therapeutics announces initiation of phase 3 trial of EDSIVO in vEDS. |
|
|
Jun 27, 2022 |
182 |
| Adial Pharmaceuticals announces database lock for ONWARD Phase 3 trial. |
|
|
Jun 27, 2022 |
294 |
| Kezar Life Sciences announces positive phase 2 results from Zetomipzomib trial. |
|
|
Jun 27, 2022 |
214 |
| Immunocore announces initial data from Phase 1 ImmTAV trial. |
|
|
Jun 26, 2022 |
340 |
| Vir Biotechnology announces new clinical data from broad Hepatitis B program. |
|
|
Jun 26, 2022 |
443 |
| Covid vaccines saved 20 million lives in year -but slow rollout saw 600k die; Almost two-thirds of the world's population has now received at least one dose since the first Covid-19vaccine was administered outside of a clinical trial. |
By, Danny Halpin & Adam May |
|
Jun 26, 2022 |
1032 |
| Ionis announces presentation of Phase 2b data for chronic hepatitis B treatment. |
|
|
Jun 25, 2022 |
322 |
| Revive Therapeutics provides update on Phase 3 trial for bucillamine in COVID-19. |
|
|
Jun 24, 2022 |
203 |
| Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA. |
|
|
Jun 24, 2022 |
235 |
| Lifecare has initiated clinical studies of the smallest glucose sensor in the world for people diagnosed with diabetes. |
|
|
Jun 24, 2022 |
1266 |
| Galderma Touts Positive Data from Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis. |
|
|
Jun 23, 2022 |
189 |
| First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China. |
|
|
Jun 23, 2022 |
194 |
